

## BREAST ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs		
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS					
SWOG	S1007-Breast,Adj,N1,Endocrine+/-Chemo	1	Y	1	Recurrence Score testing	9400	9383	0	0	0	0	0	02/28/2011	394	190
							9383	0	0	0	0	0			
		2	Y	2	Chemo and Endocrine Therapy	5000	2547	0	0	0	0	0	02/28/2011		
				3	Endocrine Therapy Alone		2536	0	0	0	0	0			
							5083	0	0	0	0	0			
	S1207-Brst,Adj,Endocrine+/-Everolimus	1	Y	1	Blinded drug + Endocrine	1900	878	175	82	46	13	2	09/12/2013	435	209
				2	Blinded drug + Endocrine		886	176	83	44	21	5			
							1764	351	165	90	34	7			
	S1222-Brst,Fulv. +/- Ever. +/- Anastr.	1	T	1	Blinded treatment	840	12	0	0	0	0	0	05/15/2014	13	3
				2	Blinded treatment		12	0	0	0	0	0			
				3	Blinded treatment		13	0	0	0	0	0			
							37	0	0	0	0	0			
	S1416-Brst, TNBC/BRCA, Cis+/- ABT-888	1	Y	1	Blinded Drug + Cisplatin	333	135	50	12	11	5	1	09/15/2016	263	130
				2	Blinded Drug + Cisplatin		139	54	18	16	3	0			
							274	104	30	27	8	1			
	S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1	Y	1	Tissue for PD-L1 testing	1000	359	250	136	67	30	7	01/18/2017	464	210
							359	250	136	67	30	7			
		2	Y	2	Observation	1000	149	100	53	25	9	0	01/18/2017		
				3	MK-3475 (Pembrolizumab)		149	106	58	29	9	2			
							298	206	111	54	18	2			
Yes	A011106-Breast, Neoadj, ALTERNATE study	1	E		Total Registrations		80	29	23	8	4	0	04/29/2014		119
							80	29	23	8	4	0			
	E1Z11-Brst,Genetic Predictors of AIMSS	1	E		Total Registrations		156	12	6	3	0	0	08/13/2013		24
							156	12	6	3	0	0			
	NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo	1	E		Total Registrations		66	21	10	7	2	0	10/16/2015		172
							66	21	10	7	2	0			
	NRGBR005-Br, Stg II&III, Post NAdj Chemo Br Conserv	1	E		Total Registrations		4	4	4	3	0	0	06/22/2018	31	18
							4	4	4	3	0	0			

## BREAST ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
					LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
No	A011401-Breast, adj, Stage II/III HER2-, weight loss	1 E Total Registrations		191	107	54	21	5	0	10/05/2016		242
				191	107	54	21	5	0			
		2 E Total Registrations		175	101	54	21	7	0	10/05/2016		
				175	101	54	21	7	0			
	A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	1 E Total Registrations		60	40	19	10	4	1	03/20/2017	444	227
				60	40	19	10	4	1			
	A221405-Breast, ET interruption, Pregnancy Outcomes	1 E Total Registrations		13	8	4	1	0	0	05/08/2017	108	53
				13	8	4	1	0	0			
	B51-Breast, Regional Nodal XRT	1 E Total Registrations		32	9	7	3	0	0	06/13/2014		208
				32	9	7	3	0	0			
	B55-Brst, Adj Olaparib for BRCA,TNBC	1 E Total Registrations		68	22	10	3	1	0	12/15/2014	440	185
				68	22	10	3	1	0			
		2 E Total Registrations		32	11	7	2	0	0	12/15/2014		
				32	11	7	2	0	0			
	E2112-Brst,Adv,Exemestane+/-Entinostat	1 E Total Registrations		61	19	12	8	2	0	04/01/2015		176
				61	19	12	8	2	0			
	EA1131-Brst, TNBC, Post-op Chemo vs Obs	0 E Total Registrations		22	8	4	4	2	0	11/12/2015		132
				22	8	4	4	2	0			
		1 P Total Registrations		11	4	0	0	0	0	11/12/2015		
				11	4	0	0	0	0			
	EA1151-Brst, Tomosynthesis Mammographic Screening	1 E Total Registrations		234	234	154	71	30	3	01/30/2018	148	75
				234	234	154	71	30	3			
	NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA	1 E Total Registrations		1	0	0	0	0	0	09/22/2017	307	135
				1	0	0	0	0	0			

**16-NOV-2018 6:10**  
**BREAST Open Studies with No Registrations**

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1706 Breast, Inflammatory, RT +/- Olaparib	1 Randomization	12-Sep-18